Company
Unleash Immuno Oncolytics
Unleashing the Immune Response Against Cancer Through Stroma-Targeted Armed Oncolytic Immunotherapy
Also known as Unleash Immuno Oncolytics, Inc.
- Status
- Operatingas of 2026-09-18Source (opens in a new tab)
- Business model
- B2B
- Founded
- 2015
- Legal name
- Unleash Immuno Oncolytics, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Unleash Immuno Oncolytics is an immune-oncology company developing armed, oncolytic viruses that target both the tumor and the stromal compartment of cancers through multiple mechanisms of action in a single product
Funding snapshot
- Total raised
- $3MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $3M2018-02-16
Funding rounds
- Round, 2018
- $3M2018-02-16, SEC form D sold, 1 investor
About the company
- Status notes
- Today, the company is leveraging its experience in scientific innovation, licensing, and value creation to scout and advance new breakthrough opportunities with strong market potential.
Products
- Other
- UIO-524
Loading relationship preview